Skip to main content
Edward Hsiao, MD, Endocrinology, San Francisco, CA

EdwardC.HsiaoMD

Endocrinology • San Francisco, CA

Diabetes, Lipid Metabolism, Osteoporosis & Bone Metabolism Medicine

Assistant Professor in Residence, Internal Medicine, UCSF School of Medicine

Join to view full profile

Dr. Hsiao is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hsiao's full profile

Already have an account?

  • Office

    4150 Clement St
    # 111N
    San Francisco, CA 94121
    Phone+1 415-750-2089

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 2004 - 2009
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 2001 - 2004
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2001

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - 2025
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
    Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaDecember 12th, 2017
  • Organovo and UCSF Partner to Create 3D Bioprinted Tissues for Skeletal Disease Research
    Organovo and UCSF Partner to Create 3D Bioprinted Tissues for Skeletal Disease ResearchJune 14th, 2016
  • FDA Approves Palovarotene for Treatment of Rare Bone Disorder
    FDA Approves Palovarotene for Treatment of Rare Bone DisorderAugust 18th, 2023
  • Join now to see all

Professional Memberships

Dr. Edward Hsiao, Dr. Edward Hsiao, MD, Dr. E Hsiao, Dr. Edward C. Hsiao